Related Experiment Video
Updated: Jun 29, 2026
12:24
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease
Anna S Lok1, Leonard B Seeff, Timothy R Morgan
1Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA. aslok@umich.edu
Gastroenterology
|October 14, 2008
Summary
Maintenance peginterferon did not lower liver cancer rates in the HALT-C study. Older age, black race, and smoking were identified as key risk factors for hepatocellular carcinoma (HCC) in hepatitis C patients.
Area of Science:
- Hepatology
- Oncology
- Viral Hepatitis Research
Background:
- Hepatocellular carcinoma (HCC) incidence is rising in the US, with limited large-scale prospective data.
- The Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) cohort provides a valuable dataset for studying HCC.
- Understanding HCC incidence and risk factors in chronic hepatitis C is crucial for patient management.
Purpose of the Study:
- To evaluate HCC incidence within the HALT-C cohort.
- To identify risk factors associated with HCC development in patients with chronic hepatitis C.
- To assess the impact of maintenance peginterferon therapy on HCC incidence.
Main Methods:
- Prospective analysis of 1,005 patients with bridging fibrosis or cirrhosis from the HALT-C cohort.
- Randomization to maintenance peginterferon or no treatment for 3.5 years.
- Kaplan-Meier analysis for HCC incidence and Cox regression for risk factor identification.
Main Results:
- During a median follow-up of 4.6 years, 4.8% of patients developed HCC.
- Cumulative 5-year HCC incidence was similar between peginterferon and control groups (5.4% vs. 5.0%).
- HCC incidence was higher in patients with cirrhosis compared to bridging fibrosis (7.0% vs. 4.1%).
- A multivariate model identified older age, black race, lower platelet count, higher alkaline phosphatase, esophageal varices, and smoking as HCC risk factors.
Conclusions:
- Maintenance peginterferon therapy did not significantly reduce HCC incidence in this cohort.
- Baseline clinical and laboratory features effectively predict HCC risk.
- Further research is needed to confirm HCC occurrence in patients with chronic hepatitis C and bridging fibrosis.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...